SEC Form 4	
------------	--

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287
Estimated average bur	den
hours per response:	0.5

	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
--	--

FORM 4

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

							uon 30(n)	or the	mvesime		mpany Act	01 1940									
1. Name and Address of Reporting Person* Brainard Diana					2. Issuer Name and Ticker or Trading Symbol Allovir, Inc. [ALVR]							(Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)								
								-						X	Director			10% Ov	wner		
			<i></i>		- -			-						- x	Officer (below)	give title		Other (s below)	specify		
(Last) (First) (Middle)						3. Date of Earliest Transaction (Month/Day/Year) 05/17/2021								,	ief Exec	utivo	,				
C/O ALLOVIR, INC.					1 0.	J/1//	2021								CI	lief Exec	uuve	Officer			
139 MAIN STREET, SUITE 500																					
(Street)					- 4.	4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line)								blicable							
CAMBR	IDGE M	1A	02142											2	X Form filed by One Reporting Person						
					-	Form filed by More than One Reporting Person									rting						
(City)	(5	State)	(Zip)																		
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
1. Title of Security (Instr. 3) 2. Trans Date (Month/						Execution if any	A. Deemed Execution Date, f any Month/Day/Year)		3. Transaction Code (Instr. 8)					Beneficia Owned Fe	s For ally (D) ollowing (I)		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership			
									Code	v	Amount	(A (D	or	Price	Reported Transacti (Instr. 3 a	on(s)			(Instr. 4)		
Common Stock 05/1				17/20	/2021			A		30,000 ⁽¹⁾		A	\$0.00	36,300			D				
Common Stock 05/17				17/20	7/2021			A		170,000 ⁽²⁾ A		A	\$0.00) 206,300			D				
			Table II -	Deriv	/ative	e Sec	curities	Acq	uired, I	Disp	osed of	, or Be	nefic	ially (Dwned						
											converti										
Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	ate,	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date E Expiratio (Month/D	n Dat	of Securities		urity	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction	e s dly D	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownershi ct (Instr. 4)			
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	or Nu	nount mber Shares		(Instr. 4)	011(3)				
Stock Option (Right to Buy)	\$23.74	05/17/2021			A	500,000		(3)		05/17/2031	Common Stock 500		0,000	\$0.00	500,000		D				

Explanation of Responses:

1. The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. These RSUs shall vest in full on May 17, 2022.

2. The shares reported in this transaction represent RSUs issued under the Plan. 25% of these RSUs shall vest on May 17, 2022, with the remainder vesting in twelve quarterly installmenters thereafter.

3. 25% of this option shall vest and become exercisable on May 17, 2022, with the remainder vesting in twelve quarterly installments thereafter.

Remarks:

/s/ Brett Hagen, as Attorney-in-05/18/2020 Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.